InspireMD chair to retire after 2027 meeting
InspireMD, Inc. reported that Board Chair Paul Stuka has decided not to seek reelection as a Class I director at the company’s 2027 Annual Meeting of Stockholders and plans to retire from the Board at that time.
Rhea-AI Filing Summary
InspireMD, Inc. reported that Board Chair Paul Stuka has decided not to seek reelection as a Class I director at the company’s 2027 Annual Meeting of Stockholders and plans to retire from the Board at that time.
The company states that his decision does not result from any disagreement regarding operations, policies, or practices. Stuka currently serves as Chair of the Board, Chair of the Compensation Committee, and as a member of the Audit and Nominating and Corporate Governance Committees, and he expects to continue in these roles until his term expires. The Nominating and Corporate Governance Committee plans to identify and evaluate suitable candidates as part of Board succession planning.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Notification date: May 20, 2026
Retirement timing: 2027 Annual Meeting
Filing sign-off date: May 22, 2026
3 metrics
Notification date
May 20, 2026
Date Paul Stuka informed InspireMD of his decision
Retirement timing
2027 Annual Meeting
When Stuka’s term as Class I director ends
Filing sign-off date
May 22, 2026
Date the report was signed by the CEO
Key Terms
Emerging growth company, Nominating and Corporate Governance Committee, Compensation Committee, Audit Committee
4 terms
Emerging growth company regulatory
"Emerging growth company Item 5.02 Departure of Directors or Certain Officers"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Nominating and Corporate Governance Committee financial
"a member of the Audit Committee and the Nominating and Corporate Governance Committee of the Board"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
Compensation Committee financial
"the Chair of the Compensation Committee of the Board"
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
Audit Committee financial
"and a member of the Audit Committee and the Nominating and Corporate Governance Committee"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
FAQ
What Board change did InspireMD (NSPR) disclose in this 8-K?
InspireMD disclosed that Board Chair and Class I director Paul Stuka has decided not to seek reelection at the 2027 Annual Meeting and plans to retire from the Board when his current term expires, beginning a formal succession process for his roles.
When will InspireMD (NSPR) director Paul Stuka retire from the Board?
Paul Stuka plans to retire from InspireMD’s Board at the company’s 2027 Annual Meeting of Stockholders, when his current term as a Class I director ends. Until then, he expects to continue serving as Board Chair and committee member.
Did Paul Stuka cite any disagreement with InspireMD (NSPR) in his decision?
No. InspireMD states that Paul Stuka’s decision to retire and not seek reelection did not result from any disagreement with the company regarding its operations, policies, practices, or other matters, indicating a planned and orderly Board transition process.
What Board roles does Paul Stuka currently hold at InspireMD (NSPR)?
Paul Stuka is currently Chair of the Board, Chair of the Compensation Committee, and a member of the Audit Committee and the Nominating and Corporate Governance Committee. He expects to continue in these positions until his term ends at the 2027 Annual Meeting.
How is InspireMD (NSPR) handling Board succession after Paul Stuka’s planned retirement?
InspireMD’s Nominating and Corporate Governance Committee plans to identify and evaluate suitable candidates for the Board as part of succession planning, aiming to ensure an orderly transition when Paul Stuka’s Class I director term ends at the 2027 Annual Meeting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
